Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Galantamine-Memantine Combination and Kynurenine Pathway Enzyme Inhibitors in the Treatment of Neuropsychiatric Disorders
Michael Y. Bai, David B. Lovejoy, Gilles J. Guillemin, et al.
Complex Psychiatry (2021) Vol. 7, Iss. 1-2, pp. 19-33
Open Access | Times Cited: 25

Showing 25 citing articles:

Immune Influencers in Action: Metabolites and Enzymes of the Tryptophan-Kynurenine Metabolic Pathway
Masaru Tanaka, Fanni Tóth, Helga Polyák, et al.
Biomedicines (2021) Vol. 9, Iss. 7, pp. 734-734
Open Access | Times Cited: 177
The Influence of Kynurenine Metabolites on Neurodegenerative Pathologies
Suhrud Pathak, Rishi Nadar, Shannon Kim, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 853-853
Open Access | Times Cited: 28
Immune Influencers in Action: Metabolites and Enzymes of the Tryptophan-Kynurenine Metabolic Pathway
Masaru Tanaka, Fanni Tóth, Helga Polyák, et al.
(2021)
Open Access | Times Cited: 93
IDO/kynurenine pathway in cancer: possible therapeutic approaches
Eslam E. Abd El-Fattah
Journal of Translational Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 58
Research progress on the kynurenine pathway in the prevention and treatment of Parkinson’s disease
Ping Chen, Xiaofei Geng
Journal of Enzyme Inhibition and Medicinal Chemistry (2023) Vol. 38, Iss. 1
Open Access | Times Cited: 26
The Impact of C-3 Side Chain Modifications on Kynurenic Acid: A Behavioral Analysis of Its Analogs on Motor Domain
Diána Martos, Bálint Lőrinczi, István Szatmári, et al.
(2024)
Open Access | Times Cited: 12
The Impact of C-3 Side Chain Modifications on Kynurenic Acid: A Behavioral Analysis of Its Analogs in the Motor Domain
Diána Martos, Bálint Lőrinczi, István Szatmári, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3394-3394
Open Access | Times Cited: 12
The chronic unpredictable mild stress (CUMS) Paradigm: Bridging the gap in depression research from bench to bedside
Shweta Sharma, Shivani Chawla, Praveen Kumar, et al.
Brain Research (2024) Vol. 1843, pp. 149123-149123
Closed Access | Times Cited: 9
The Biology and Biochemistry of Kynurenic Acid, a Potential Nutraceutical with Multiple Biological Effects
Luana de Fátima Alves, J. Bernadette Moore, Douglas B. Kell
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 16, pp. 9082-9082
Open Access | Times Cited: 6
Identification of potent inhibitors of kynurenine-3-monooxygenase from natural products: In silico and in vitro approaches
Redouane Rebai, Miguel Carmena‐Bargueño, Mohammed Esseddik Toumi, et al.
Heliyon (2024) Vol. 10, Iss. 9, pp. e30287-e30287
Open Access | Times Cited: 5
Comprehensive evaluation of 45 augmentation drugs for schizophrenia: a network meta-analysis
Damien Etchecopar‐Etchart, Dong Keon Yon, Piotr Wojciechowski, et al.
EClinicalMedicine (2024) Vol. 69, pp. 102473-102473
Open Access | Times Cited: 4
Importance of the dysregulation of the kynurenine pathway on cognition in schizophrenia: a systematic review of clinical studies
Jacopo Sapienza, Marco Spangaro, Gilles J. Guillemin, et al.
European Archives of Psychiatry and Clinical Neuroscience (2022) Vol. 273, Iss. 6, pp. 1317-1328
Closed Access | Times Cited: 17
Treatment-resistant depression: molecular mechanisms and management
Mayanja Kajumba, Angelina Kakooza‐Mwesige, Noeline Nakasujja, et al.
Molecular Biomedicine (2024) Vol. 5, Iss. 1
Open Access | Times Cited: 3
Implications of Kynurenine Pathway Metabolism for the Immune System, Hypothalamic–Pituitary–Adrenal Axis, and Neurotransmission in Alcohol Use Disorder
Bartosz Osuch, Tomasz Misztal, Kinga Pałatyńska, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 9, pp. 4845-4845
Open Access | Times Cited: 2
The Tryptophan Metabolite Indole-3-Propionic Acid Raises Kynurenic Acid Levels in the Rat Brain In Vivo
Korrapati V. Sathyasaikumar, Tonali Blanco Ayala, Yiran Zheng, et al.
International Journal of Tryptophan Research (2024) Vol. 17
Open Access | Times Cited: 2
Blueberry extract for the treatment of ischaemic stroke through regulating the gut microbiota and kynurenine metabolism
Raoqiong Wang, Guoxin Huang, Shuangyang Li, et al.
Phytotherapy Research (2024) Vol. 38, Iss. 9, pp. 4792-4814
Closed Access | Times Cited: 2
The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: a systematic review and meta-analysis of cerebrospinal fluid studies
Mehmet Enes Inam, Brisa S. Fernandes, Estela Salagre, et al.
Brazilian Journal of Psychiatry (2023)
Open Access | Times Cited: 6
Integrative Pharmacology in the Treatment of Substance Use Disorders
Jack Donlon, Pooja Kumari, Sajoy P. Varghese, et al.
Journal of Dual Diagnosis (2023) Vol. 20, Iss. 2, pp. 132-177
Closed Access | Times Cited: 6
Time-resolved map of serum metabolome profiling in D-galactose-induced aging rats with exercise intervention
Xue Li, Changling Wei, Jin Yu, et al.
iScience (2024) Vol. 27, Iss. 2, pp. 108999-108999
Open Access | Times Cited: 1
Pharmacological Treatments of Negative Symptoms in Schizophrenia—An Update
Eva-Maria Tsapakis, Michael Treiber, Calypso Mitkani, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 18, pp. 5637-5637
Open Access | Times Cited: 1
The Role of Neuroglia in the Development and Progression of Schizophrenia
Neha S. Rawani, Allen W. Chan, Kathryn G. Todd, et al.
Biomolecules (2024) Vol. 15, Iss. 1, pp. 10-10
Open Access | Times Cited: 1
Design, Synthesis and Evaluation of Catechol-Based Amyloid Beta Aggregation Inhibitors
Hiroyuki Konno, Kenta Teruya
Heterocycles (2023) Vol. 106, Iss. 5, pp. 797-797
Open Access | Times Cited: 3
Antidepressant-like Effects of Kynurenic Acid Analogues
Masaru Tanaka, Ágnes Szabó, Bálint Lőrinczi, et al.
(2021), pp. 10301-10301
Open Access | Times Cited: 7
Galantamine-Memantine Combination in the Treatment of Parkinson’s Disease Dementia
Emma D. Frost, Shuyan Shi, Vishnu Byroju, et al.
Brain Sciences (2024) Vol. 14, Iss. 12, pp. 1163-1163
Open Access
Therapeutic Considerations in HIV-Associated Neurocognitive Disorders (HAND)
Adam Adelsberg, Dennis L. Kolson
NeuroImmune Pharmacology and Therapeutics (2024), pp. 719-742
Closed Access
Page 1

Scroll to top